311 related articles for article (PubMed ID: 21765211)
1. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice.
Lesterhuis WJ; Punt CJ; Hato SV; Eleveld-Trancikova D; Jansen BJ; Nierkens S; Schreibelt G; de Boer A; Van Herpen CM; Kaanders JH; van Krieken JH; Adema GJ; Figdor CG; de Vries IJ
J Clin Invest; 2011 Aug; 121(8):3100-8. PubMed ID: 21765211
[TBL] [Abstract][Full Text] [Related]
2. Alternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PD-L2.
Huber S; Hoffmann R; Muskens F; Voehringer D
Blood; 2010 Oct; 116(17):3311-20. PubMed ID: 20625006
[TBL] [Abstract][Full Text] [Related]
3. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal Stem Cells Inhibited Dendritic Cells Via the Regulation of STAT1 and STAT6 Phosphorylation in Experimental Autoimmune Uveitis.
Dong L; Chen X; Shao H; Bai L; Li X; Zhang X
Curr Mol Med; 2018 Mar; 17(7):478-487. PubMed ID: 29424313
[TBL] [Abstract][Full Text] [Related]
5. STATing the importance of immune modulation by platinum chemotherapeutics.
Hato SV; de Vries IJ; Lesterhuis WJ
Oncoimmunology; 2012 Mar; 1(2):234-236. PubMed ID: 22720254
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin ototoxicity involves cytokines and STAT6 signaling network.
Kim HJ; Oh GS; Lee JH; Lyu AR; Ji HM; Lee SH; Song J; Park SJ; You YO; Sul JD; Park C; Chung SY; Moon SK; Lim DJ; So HS; Park R
Cell Res; 2011 Jun; 21(6):944-56. PubMed ID: 21321603
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
Liu Y; Huang H; Chen Z; Zong L; Xiang J
J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
[TBL] [Abstract][Full Text] [Related]
8.
Bamodu OA; Kuo KT; Wang CH; Huang WC; Wu ATH; Tsai JT; Lee KY; Yeh CT; Wang LS
Nutrients; 2019 Sep; 11(10):. PubMed ID: 31547048
[TBL] [Abstract][Full Text] [Related]
9. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade.
Fu J; Kanne DB; Leong M; Glickman LH; McWhirter SM; Lemmens E; Mechette K; Leong JJ; Lauer P; Liu W; Sivick KE; Zeng Q; Soares KC; Zheng L; Portnoy DA; Woodward JJ; Pardoll DM; Dubensky TW; Kim Y
Sci Transl Med; 2015 Apr; 7(283):283ra52. PubMed ID: 25877890
[TBL] [Abstract][Full Text] [Related]
10. Fine-tuned expression of programmed death 1 ligands in mature dendritic cells stimulated by CD40 ligand is critical for the induction of an efficient tumor specific immune response.
Gu T; Zhu YB; Chen C; Li M; Chen YJ; Yu GH; Ge Y; Zhou SY; Zhou H; Huang Y; Qiu YH; Zhang XG
Cell Mol Immunol; 2008 Feb; 5(1):33-9. PubMed ID: 18318992
[TBL] [Abstract][Full Text] [Related]
11. IL-4-induced activation of the Stat6 pathway contributes to the suppression of cell-mediated immunity and death in sepsis.
Song GY; Chung CS; Chaudry IH; Ayala A
Surgery; 2000 Aug; 128(2):133-8. PubMed ID: 10922982
[TBL] [Abstract][Full Text] [Related]
12. Piperine Ameliorates Trimellitic Anhydride-Induced Atopic Dermatitis-Like Symptoms by Suppressing Th2-Mediated Immune Responses via Inhibition of STAT6 Phosphorylation.
Choi DW; Jung SY; Shon DH; Shin HS
Molecules; 2020 May; 25(9):. PubMed ID: 32392825
[TBL] [Abstract][Full Text] [Related]
13. STAT Family Protein Expression and Phosphorylation State during moDC Development Is Altered by Platinum-Based Chemotherapeutics.
de Haas N; de Koning C; di Blasio S; Flórez-Grau G; de Vries IJM; Hato SV
J Immunol Res; 2019; 2019():7458238. PubMed ID: 31309123
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade.
Wakita D; Iwai T; Harada S; Suzuki M; Yamamoto K; Sugimoto M
Anticancer Res; 2019 Apr; 39(4):1749-1760. PubMed ID: 30952714
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics.
Hato SV; Khong A; de Vries IJ; Lesterhuis WJ
Clin Cancer Res; 2014 Jun; 20(11):2831-7. PubMed ID: 24879823
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin induces tolerogenic dendritic cells in response to TLR agonists via the abundant production of IL-10, thereby promoting Th2- and Tr1-biased T-cell immunity.
Kim WS; Kim H; Kwon KW; Im SH; Lee BR; Ha SJ; Shin SJ
Oncotarget; 2016 Jun; 7(23):33765-82. PubMed ID: 27172902
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
18. [Effect of cisplatin alone or combined with monoclonal anti-programmed death ligand-1 antibody on lung adenocarcinoma cell line SPCA-1 and T lymphocytes].
Pan X; Xing Y; Shi M; Zhou T; Qian B; Chen Y
Zhonghua Jie He He Hu Xi Za Zhi; 2014 Jun; 37(6):416-20. PubMed ID: 25200040
[TBL] [Abstract][Full Text] [Related]
19. Stat6 Promotes Intestinal Tumorigenesis in a Mouse Model of Adenomatous Polyposis by Expansion of MDSCs and Inhibition of Cytotoxic CD8 Response.
Jayakumar A; Bothwell ALM
Neoplasia; 2017 Aug; 19(8):595-605. PubMed ID: 28654863
[TBL] [Abstract][Full Text] [Related]
20. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
